# NCT02335424 (NCT02335424)

> Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02335424
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Urothelial Cancer
- Interventions: pembrolizumab
- Enrollment: 374
- Primary outcome: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants
- Primary outcome: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥1%
- Primary outcome: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥10%

## Commentary we found

- YouTube: 5
- Podcasts: 5
- X threads: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct02335424

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02335424", "email": "<work email>"}; the inbox owner confirms by the emailed link.